{
    "clinical_study": {
        "@rank": "83788", 
        "arm_group": [
            {
                "arm_group_label": "Immunoglobulin Anti-RhD", 
                "arm_group_type": "Experimental", 
                "description": "KamRho-D (Panamerican)"
            }, 
            {
                "arm_group_label": "Rhophylac", 
                "arm_group_type": "Active Comparator", 
                "description": "Rhophylac (CSL Behring)"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this trial is that the test drug (KamRho-D \u00ae - T) is not inferior to the\n      comparator drug (Rhophylac \u00ae - C) for immunization of Rh negative mothers at risk of\n      sensitization. The primary aim is to evaluate the clinical non-inferiority of the test drug\n      (KamRho-D \u00ae - Panamerican) compared to the comparator drug (Rhophylac \u00ae - CSL Behring) after\n      passive immunization in Rh-negative mothers, negative indirect Coombs, whose baby is Rh\n      positive, through the incidence of non positivization of the indirect Coombs test 06 months\n      after delivery. The secondary objective is to assess aspects of drug safety, such as: type,\n      frequency and intensity of adverse events between groups."
        }, 
        "brief_title": "Non-inferiority of Immunoglobulin Anti-RhD KamRho-D\u00ae Compared to Rhopphylac\u00ae in Postpartum Immunization of Rh-negative, Coombs Negative Women at Risk of Sensitization.", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prevention of Rh Sensitization During Pregnancy", 
        "condition_browse": {
            "mesh_term": "Rh Isoimmunization"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agree to participate, sign and date the Informed Consent;\n\n          -  18 years old or older;\n\n          -  Mothers who are Rh-negative, negative indirect Coombs analyzed by gel agglutination\n             method, whose just deliveries Rh positive baby.\n\n        Exclusion Criteria:\n\n          -  Be participating simultaneously or have participated in another clinical trial within\n             the last 12 months;\n\n          -  Mothers who are allergic to any components of the formula;\n\n          -  Mothers who have a history of IgA deficiency or IgA antibody present;\n\n          -  Mothers who have a history of autoimmune hemolytic anemia with hemolysis or with\n             pre-existing risk of hemolysis;\n\n          -  Mothers who have indirect Coombs test positive in the beginning of the treatment;\n\n          -  Rh-negative mothers whose delivered Rh-negative babies;\n\n          -  Abnormalities of the coagulation system;\n\n          -  Patients who made use of vaccines made \u200b\u200bwith live pathogens in the last 03 months or\n             will make during the study;\n\n          -  Patients with clinical diagnosis of prenatal liver and / or severe nephropathy;\n\n          -  Principal Investigator of the study criteria;"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "232", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666249", 
            "org_study_id": "IMUPAN1011", 
            "secondary_id": "Version 1 from 1/10/2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Immunoglobulin Anti-RhD", 
                "description": "KamRho-D (Immunoglobulin Anti-RhD): single dose (300mcg/2mL), via intramuscular, up to 72h after delivery.", 
                "intervention_name": "Immunoglobulin Anti-RhD", 
                "intervention_type": "Biological", 
                "other_name": [
                    "KamRho-D", 
                    "Rhophylac"
                ]
            }, 
            {
                "arm_group_label": "Rhophylac", 
                "description": "Single dose (300 mcg/2 mL), via intramuscular, up to 72h after delivery.", 
                "intervention_name": "Rhophylac", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 10, 2012", 
        "location": [
            {
                "contact": {
                    "email": "obstetriciapucrs@hotmail.com", 
                    "phone": "+55 51 3320-3479"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul", 
                        "zip": "90610-000"
                    }, 
                    "name": "Hospital S\u00e3o Lucas (Puc-Rs)"
                }, 
                "investigator": {
                    "last_name": "Julia de Barros Machado", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cepes@fmabc.br", 
                    "last_name": "Edna Oliveira de Souza", 
                    "phone": "+55 11 49935410"
                }, 
                "facility": {
                    "address": {
                        "city": "Santo Andr\u00e9", 
                        "country": "Brazil", 
                        "state": "S\u00e3o Paulo", 
                        "zip": "09060-650"
                    }, 
                    "name": "Cepes - Faculdade de Medicina Do Abc"
                }, 
                "investigator": {
                    "last_name": "Mauro Sancovski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of the Evaluation of the Non-inferiority of Immunoglobulin Anti-RhD KamRho-D\u00ae (Panamerican) Compared to Rhopphylac\u00ae (CSL Behring)in Postpartum Immunization of Rh-negative, Coombs Negative Women at Risk of Sensitization.", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico", 
            "phone": "+55 11 38716399"
        }, 
        "overall_official": {
            "affiliation": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
            "last_name": "Alexandre Frederico, Physician", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint will be the maintenance of the negative result for the indirect Coombs test 06 months after delivery, proving that the test drug and the comparator drug had the same ability to neutralize possible fetal red blood cells.", 
            "safety_issue": "Yes", 
            "time_frame": "72 (+6) hours after immunization; 90 days after immunization and 180 days after immunization."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence, intensity, type and frequence of adverse event.", 
            "safety_issue": "Yes", 
            "time_frame": "180 days"
        }, 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}